Recursion Pharmaceuticals

RXRX Small Cap

Healthcare · Biotechnology

Updated: Apr 5, 2026, 17:43 UTC

$3.11

+1.63% today

52W: $2.80 – $7.18

52W Low: $2.80 Position: 7.1% 52W High: $7.18

🔗 Compare Brokers Best Broker for Beginners →

Key Metrics

P/E Ratio

—

Price-to-Earnings

Forward P/E

—

Forward Price/Earnings

P/S Ratio

22x

Price-to-Sales

EV/EBITDA

—

Enterprise Value/EBITDA

Div. Yield

—

Annual dividend yield

Market Cap

$1.6B

Market Capitalization

Revenue Growth

681.7%

YoY Revenue Growth

Profit Margin

—

Net profit margin

ROE

-59.54%

Return on Equity

Beta

1.01

Market sensitivity

Short Interest

34.89%

% of float sold short

Avg. Volume

18,691,918

Average daily volume

Valuation Analysis

Signal

N/A

vs. S&P 500 avg P/E (24.7x)

Analyst Consensus

None

7 analysts

Avg. Price Target

$6.71

+115.89% upside

Target Range

$3.00 – $11.00

About the Company

Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1

Sector: Healthcare Industry: Biotechnology Country: United States Employees: 600 Exchange: NMS